Effects of fosinopril on renal function in patients with mild to moderate essential hypertension

Clinical Drug Investigation

Volumn 12, Issue 5, 1996, Pages 251-258

  Zamboulis, Chrysanthos ^a   Karagiannis, Asterios ^a,c   Gotzamani Psarrakou, Anna ^b   Deligianni, Kalliopi ^a   Spyridonidis, Tryfon ^b   Fragos, Savas ^b   Psarrakos, Kyriakos ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Ippokration Hospital   (Greece)

^c NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; FOSINOPRIL; RENIN;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; FEMALE; GLOMERULUS FILTRATION RATE; HEART RATE; HEMODYNAMICS; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MALE; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; URINALYSIS;

EID: 0029833175     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199612050-00004     Document Type: Article

References (37)

1. Morrison RA, Singhvi SM, Pocetti D, et al. Sites of first-pass bioactivation of fosinopril sodium in dogs [abstract 230]. Pharmacologist 1987; 29: 149
2. DeForrest JM, Waldron TL, Harvey C, et al. Fosinopril, a phosphinic acid inhibitor of angiotensin 1 converting enzyme: in vitro and pre-clinical in vivo pharmacology. J Cardiovasc Pharmacol 1989; 14: 730-6
3. Brochner-Mortensen J. Routine methods and their reliability for assessment of glomerular filtration rate. Br Med Bull 1978; 25: 5
4. Fleming JS, Wilkinson J, Oliver RM, et al. Comparison of radionuclide estimation of glomerular filtration rate using technetium 99m DTPA and chromium 51 EDTA. Eur J Nucl Med 1991; 18: 391-5
5. Tauxe WN, Dubovsky EV, Kidd T Jr, et al. New formulas for the calculation of effective renal plasma flow. Eur J Nucl Med 1982; 7: 51-4
6. Bubeck B. Technetium-99m-MAG 3 für die nuklear-medizinische Nierefunktionsdiagnostik. Pharmakokinetik und klinische Anwendurg im Vergleich mit radiojodierter Hippursaeure. Toronto: Hans Huber, 1991
7. Bubeck B, Piepenburg R, Grethe U, et al. A new principle to normalise plasma concentrations allowing single-sample-clearance determinations in both children and adults. Eur J Nucl Med 1992; 19: 511-6
8. Krapcho J, Turk C, Cushman DW, et al. Angiotensin convening enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide and phosphinic acid inhibitors incorporating 4-substituted prolines. J Med Chem 1988; 31: 1148-60
9. Fruncillo RJ, Rocci ML, Vlasses PH, et al. Disposition of enalapril and enalaprilat in renal insufficiency. Kidney Int 1987; 31 Suppl. 20: S117-S122
10. Gautam PC, Vargas E, Lye M. Pharmacokinetics of lisinopril (MK 521) in healthy young and elderly subjects and in elderly patients with cardiac failure. J Pharm Pharmacol 1987; 39: 929-31
11. Shionoiri H, Minamisawa K, Ueda S, et al. Pharmacokinetics and antihypertensive effects of lisinopril in hypertensive patients with normal and impaired renal function. J Cardiovasc Pharmacol 1990; 16: 594-600
12. Singhvi S, Duchin KL, Morrison RA, et al. Disposition of fosinopril sodium in healthy subjects. Br Clin Pharmacol 1988; 25: 9-15
13. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Captopril: evaluation of low doses, twice-daily doses and the addition of diuretic for the treatment of mild to moderate hypertension. Clin Sci 1982; 63: S443-S445
14. Davis RO, Gomez HJ, Irvin JR, et al. An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol 1984; 18: S215-S229
15. Clement DL. Calcium antagonists in the treatment of essential hypertension: overview of international studies. J Clin Pharmacol 1989; 13 Suppl. 4: S7-S11
16. Andrew L, Svennsson A, Hansson L, Captopril or atenolol in essential hypertension. Acta Med Scand 1983; 677: 115-8
17. Corea L, Beutivoglio M, Verdecchia P, et al. Converting enzyme inhibition vs diuretic therapy as first therapeutic approach to the elderly hypertensive patient. Curr Ther Res 1984; 36: 347-51
18. Hollenberg NK, Meggs LG, Williams GH, et al. Sodium intake and renal responses to captopril in normal man and in essential hypertension. Kidney Int 1984; 20: 240-5
19. Mimran A, Brunner HR, Turini GA, et al. Effect of captopril on renal vascular tone in patients with essential hypertension. Clin Sci 1979: 57: 421s-423s
20. Hollenherg NK, Swartz SL, Passan DR, et al. Increased glomerular filtration rate alter converting enzyme inhibition in essential hypertension. N Engl J Med 1979; 301: 9-12
21. De Zeeuw D, Navis GJ, Donker AJM, et al. The angiotensin converting enzyme inhibitor enalapril and its effects on renal function. J Hypertens 1983; 1 Suppl. 1: 93-7
22. Bauer JH, Reams GP. Renal effects of angiotensin converting enzyme inhibitors in hypertension. Am J Med 1986; 81 Suppl. 4C: 19-27
23. Ventura H, Frohlich ED, Messerli F, et al. Cardiovascular effects and regional blood flow distribution associated with angiotensin-converting enzyme inhibition (captopril) in essential hypertension. Am J Cardiol 1985; 55: 1023-6
24. Garavaglia GE, Messerli FH, Nunez BD, et al. Immediate and short term cardiovascular effects of a new converting enzyme inhibitor (lisinopril) in essential hypertension. Am J Cardiol 1988; 62: 912-7
25. Reams GP, Bauer JH. Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. Arch Intern Med 1986; 146: 2145-8
26. Piepzs A, Tondeur M, Kinthaert J, et al. Reproducibility of technetium-99m mercaptoacetyltriglycine clearance. Eur J Nucl Med 1996; 23: 195-8
27. Bubeck B. Methodology: quantitative evaluation of clearance. In: Murray IPC, Ell PJ, editors. Nuclear medicine in clinical diagnosis and treatment. Vol. 1. Hong Kong: Churchill Livingstone, 1995
28. Brunner HR. ACE inhibitors in renal disease. Kidney Int 1992; 42: 463-79
29. Sealey JE, Overlack A, Laragh JH, et al. Effect ot captopril and aprotinin on inactive renin. J Clin Endocrinol Metab 1981; 53: 626-30
30. Goldstone R, Horion R, Carlson EJ, et al. Reciprocal changes in active and inactive renin after converting enzyme inhibition in normal man. J Clin Endocrinol Metab 1983; 56: 264-8
31. Malatino LS, Manhem P, Ball SG, et al. Twenty-four hours changes in active and inactive renin after various oral doses of the converting enzyme inhibitor ramipril (HOE 498) in normal man. J Clin Hypertens 1986; 3: 231-7
32. Nussberger J, De Gasparo M, Juillerat L, et al. Rapid measurement ot total and active renin plasma concentrations during acute and sustained converting enzyme inhibition with CGS 14824A. Clin Exp Hypertens 1987; A9: 1353-66
33. Brunner HR, Waeber B, Nussberger J. Angiotensin-converting enzyme inhibition versus blockade of the renin-angiotensin system. Am J Med 1989; 87 Suppl. 6B: S15-S18
34. Nussberger J, Wacber B, Brunner HR. Plasma angiotensin II and the antihypertensive action of angiotensin-converting enzyme inhibition. Am J Hypertens 1989; 2: 286-93
35. Juillerat L, Nussberger J, Menard J, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990; 16: 564-72
36. Mooser V, Nussberger J, Juillerat L, et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990; 15: 276-82
37. Borghi C, Boschi S, Ambrosioni E, et al. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993; 33: 40-5